Company Overview and News
The recent souring of relationship between the United States and Turkey and the consequent plunge in lira appears to be rattling global markets more than was probably feared. World stocks touched a one-month low to start this week as investors dumped equities, especially the ones from emerging markets and sought shelter under safe havens.
ACWI DIA EZU VGK AIA EEM
The Turkish lira is down more than 40% year to date, with Friday's fall alone reaching 18.5% at one point and ending down 14.3% for the day. While Turkey's economy is not large, some major European banks have big exposures in non-lira loans. The European Central Bank is reported to be concerned about the vulnerability of such banks, in particular, BBVA, UniCredit (OTCPK:UNCFF) and BNP (OTCQX:BNPQF).
TUR EWG EZU VWO
The selloff in the lira, double-digit inflation, aftereffects of policy tightening in the United States political woes and persistent concerns about economic stability have dealt a heavy blow to Turkey stocks this year. Turkey ETF dropped to a nine-year low in Q2. iShares MSCI Turkey ETF (TUR - Free Report) was off 52.2% this year (read: Best & Worst Zones of 1H 2018 and Their ETFs).
ACWI FOX TUR DIA EZU EDZ SH VGK EFZ SDOW SPDN DXD FOXA EEM
Geopolitical tensions, oil price movement and President Trump’s protectionist trade announcements hit the headlines in Q2. The President made impactful announcements pertaining to deregulations, trade relations with other countries and sanctions against countries like Iran and Venezuela.
EWJ BLT BHPBF EZU VGK FLOT SCHP IVV SHV BHP BBL BHP IVV BHPLF EEM
Stocks across the globe have suffered their worst first half in a year since 2010, wiping out trillions of dollars from the MSCI’s 47-country world index. A combination of tariff tantrums, broad tech sell-off, the prospect of end to the cheap money era and cooling growth in many parts of the economy including Europe and Japan resulted in huge capital outflows from the market. Additionally, the strength in the U.
AGG IVV VEA SHV VOO SPY EZU IVV EFA FLOT EEM
The global market was subdued in the second quarter of 2018 due to trade war fears, a slowdown in activity and political crisis. Only Wall Street emerged a survivor as evident from a 4.42% three-month return by SPDR S&P 500 ETF (SPY - Free Report) .
ACWI WFC WFCNP EWJ EZU VGK AIA EEM
Geopolitical tensions, oil price movement and President Trump’s announcements hit the headlines in the month of May. Donald Trump made impactful announcements pertaining to deregulations, trade relations with other countries and sanctions against countries like Iran and Venezuela. Overall, markets remained upbeat barring some occasional dips.
AGG IVV ELY QQQ IEF VOO SPY EZU IVV IWM EEM
The latest political crisis in Italy roiled the global markets lately, pushed the euro down to a 10-month low and triggered a safe-haven rally. Along with Italy, Spain (for a different reason) is also expecting a snap election soon, spooking investors about the likely instability in the Euro zone and its aftershocks across the global asset classes.
ACWI DIA EZU EDZ SH VGK EFZ AIA SPDN SDOW EEM
In the past two weeks, investors have come, belatedly, to recognize the negative implications of the election of a populist government in Italy, the first such government in Western Europe. The possibility of a government collapse in Spain as a result of the main opposition party's call for a vote of no confidence added to investor concerns last week. Leading indicators of Eurozone business activity showed that economic growth in May, while still characterized by IHS Markit as "robust," had slowed for the fourth month in a row.
For the first week in four, investors were net redeemers of fund assets (including those of conventional funds and ETFs), withdrawing $291 million. However, the headline number was a bit misleading. While fund investors were net redeemers of money market funds (-$24.2 billion), they padded the coffers of equity funds (+$20.4 billion), taxable bond funds (+$3.2 million), and municipal bond funds (+$339 million) for the fund flows week ended March 14, 2018.
QQQ SHV EZU IEFA
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to EZU / iShares MSCI Eurozone ETF on message board site Silicon Investor.
as of ET